The DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.
Obesity and the kidney: mechanistic links and therapeutic advances
Abstract
Obesity is strongly associated with the development of diabetes mellitus and chronic kidney disease (CKD), but there is evidence for a bidirectional relationship wherein the kidney also acts as a key regulator of body weight. In this Review, we highlight the mechanisms implicated in obesity-related CKD, and outline how the kidney might modulate feeding and body weight through a growth differentiation factor 15-dependent kidney-brain axis. The favourable effects of bariatric surgery on kidney function are discussed, and medical therapies designed for the treatment of diabetes mellitus that lower body weight and preserve kidney function independent of glycaemic lowering, including sodium-glucose cotransporter 2 inhibitors, incretin-based therapies and metformin, are also reviewed. In summary, we propose that kidney function and body weight are related in a bidirectional fashion, and that this interrelationship affects human health and disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, GLP-1 receptor agonists favorably influence relevant risk factors for kidney disease, including hyperglycemia, elevated blood pressure, and increased body weight (19).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [19]
In the citing paper
“Systemic hypertension has been linked to the development of obesity-related CKD26, but we observed a direct relationship between decreases in systolic BP and decreases in eGFR at multiple time points.”
In the citing paper
“Obesity can contribute to CKD through multiple mechanisms including volume expansion (leading to glomerular hyperfiltration) and the effect of adipocytokines (leptin and aldosterone) to cause renal injury and fibrosis23,26.”
Citations
Cites
2 retracted
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01640-8 · Cited by 279 · cited 1×
“Network meta-analyses have demonstrated that GLP1RAs, particularly semaglutide, are highly effective for weight management, with a body weight change of 5.8% from baseline over a median of 24 weeks 94 .”
InfluentialRetractedTargeting the NLRP3 inflammasome to Reduce Diet-induced Metabolic Abnormalities in Mice
Chiazza, F., Couturier-Maillard, A., Benetti, E., Mastrocola, R., Nigro, D., Cutrìn, J. C., Serpe, L., Aragno, M., Fantozzi, R., Ryffel, B., et al. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00104 · Cited by 86 · cited 1×
“NLRP3 gain-of-function diabetic mice display glomerular injury and albuminuria 43 , while NLRP3 deficiency or pharmacological inhibition in mice with obesity or DKD decreases the accumulation of renal lipid droplets in association with a reduction in inflammation, fibrosis and albuminuria 49,50 .”
RetractedAbarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482 · cited 2×
“If current trends continue, by 2025, approximately 18% of men and 21% of women worldwide will have obesity 1 .”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 3×
“Unexpectedly, however, considerable benefits predominantly on heart failure and kidney outcomes were consistently observed across trials in patients with different levels of cardiovascular and kidney risk 66,67 .”
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 2×
“Bariatric surgery remains the most effective intervention for sustained weight loss over a decade 53 .”
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Epidemiology of chronic kidney disease: an update 2022
Kovesdy, C. P. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.003 · Cited by 2,973 · cited 2×
“Paralleling the increasing rates of obesity, the prevalence of chronic kidney disease (CKD) has also risen; CKD affected more than 800 million people worldwide in 2017, and remains a leading cause of morbidity and mortality 2 .”
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754 · cited 3×
“Unexpectedly, however, considerable benefits predominantly on heart failure and kidney outcomes were consistently observed across trials in patients with different levels of cardiovascular and kidney risk 66,67 .”
Influential
Cited by
Romagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodríguez-Iturbe, B., & Anders, H.-J. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00589-9 · Cited by 184
Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine · doi:10.1038/s41591-024-03374-z · Cited by 166
“Indeed, volume expansion, CKD and greater burden of hypertension best distinguish individuals from obesity-related HFpEF from age, sex and BMI-matched patients with obesity but no HF 9 .”
InfluentialXie, K., Cao, H., Ling, S., Zhong, J., Chen, H., Chen, P., & Huang, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1526482 · Cited by 147
“Research has shown that obesity is a key driver of CKD progression, with mechanisms including hemodynamic changes, in fl ammation, oxidative stress, and activation of the renin-angiotensin-aldosterone system (RAAS) (41).”
AMPK at the interface of nutrient sensing, metabolic flux and energy homeostasis
Smith, T. K. T., Townsend, L. K., Smiles, W. J., Oakhill, J. S., Fullerton, M. D., & Steinberg, G. R. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01442-3 · Cited by 64
“In diabetes-associated CKD, reduced AMPK activity is linked to impaired kidney function and increased renal hypertrophy in animal models 284,285 .”
Dong, B., Zhao, Y., Wang, J., Lu, C., Chen, Z., Ma, R., Bi, H., Wang, J., Wang, Y., Ding, X., et al. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2403645 · Cited by 48
“…kidney function screening and provision of renal protective treatments, such as aCE inhibitors and SGlt2 inhibitors, could reduce CKd incidence [32]. diabetic nephropathy (dn) is a complication of diabetic microvascular disease and has become one of the leading causes of ESRd. to prevent the…”
Metadata
- Authors
- Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- Corresponding author
- Cherney, David Z. I.
- Lam, Tony K. T.
- Venue
- Nature Reviews Endocrinology
- Published
- 2024-02-13
- Volume
- 20
- Issue
- 6
- Pages
- 321-335
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W4391773493
- Cited by
- 91
- References
- 178
- Citations by year
- 2026: 26 · 2025: 47 · 2024: 18
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › GDF15 and Related Biomarkers
- Keywords
- obesity, chronic kidney disease, kidney-brain axis, growth differentiation factor 15, bariatric surgery, diabetes mellitus, SGLT2 inhibitors, incretin-based therapy, metformin, body weight regulation, renal function
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Body Weight, Humans, Kidney, Obesity, Bariatric Surgery, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obesity and the kidney: mechanistic links and therapeutic advances. https://app.cochat.ai/papers/10.1038/s41574-024-00951-7
- The paper
- Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024). Obesity and the kidney: mechanistic links and therapeutic advances. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-024-00951-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.